Evidence map›Paper›PMID 24925725›Full record

ArticleJournal of the American Society of Nephrology : JASN2014

Lupus nephritis susceptibility loci in women with systemic lupus erythematosus.

Sharon A Chung, Elizabeth E Brown, Adrienne H Williams, Paula S Ramos, Celine C Berthier, Tushar Bhangale, Marta E Alarcon-Riquelme, Timothy W Behrens, Lindsey A Criswell, Deborah Cunninghame Graham and 20 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 4 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Lupus Nephritis Susceptibility Loci in theKidney international reports · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Does the esv3587290 Copy Number Variation in theChildren (Basel, Switzerland) · 2024
    Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 16 institutions in 4 countries.

Sharon A ChungDivision of Rheumatology, Rosalind Russell-Ephraim P. Engleman Medical Research Center for Arthritis, University of California, San Francisco, California;
Elizabeth E BrownDepartment of Epidemiology, University of Alabama, Birmingham, Alabama; Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, Birmingham, Alabama;
Adrienne H WilliamsDepartment of Biostatistical Sciences, Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina;
Paula S RamosDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina;
Celine C BerthierDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan;
Tushar BhangaleDepartment of Bioinformatics and Computational Biology, and.
Marta E Alarcon-RiquelmeArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Human DNA Variability Area, Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research, Granada, Spain;
Timothy W BehrensImmunology Tissue Growth and Repair Human Genetics Group, Genentech Inc., South San Francisco, California;
Lindsey A CriswellDivision of Rheumatology, Rosalind Russell-Ephraim P. Engleman Medical Research Center for Arthritis, University of California, San Francisco, California;
Deborah Cunninghame GrahamDivisions of Genetics and Molecular Medicine and Immunology, Infection, and Inflammatory Disease, Kings College, London, United Kingdom;
F Yesim DemirciDepartment of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania;
Jeffrey C EdbergDivision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, Birmingham, Alabama;
Patrick M GaffneyArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma;
John B HarleyArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Division of Rheumatology, Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma;
Chaim O JacobDepartment of Medicine, University of Southern California, Los Angeles, California;
M Ilyas KambohDepartment of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania;
Jennifer A KellyArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma;
Susan ManziDepartment of Medicine, West Penn Allegheny Health System, University of Pittsburgh, Pittsburgh, Pennsylvania; Temple University School of Medicine, Philadelphia, Pennsylvania;
Kathy L Moser-SivilsArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma;
Laurie P RussellDepartment of Biostatistical Sciences, Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina;
Michelle PetriDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland;
Betty P TsaoDivision of Rheumatology, Department of Medicine, University of California, Los Angeles, California;
Tim J VyseDivisions of Genetics and Molecular Medicine and Immunology, Infection, and Inflammatory Disease, Kings College, London, United Kingdom;
Raphael ZidovetzkiDepartment of Cell Biology and Neuroscience, University of California, Riverside, California; and.
Matthias KretzlerDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan;
Robert P KimberlyDivision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, Birmingham, Alabama;
Barry I FreedmanSection on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Robert R GrahamImmunology Tissue Growth and Repair Human Genetics Group, Genentech Inc., South San Francisco, California;
Carl D LangefeldDepartment of Biostatistical Sciences, Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina; clangefe@wakehealth.edu.
International Consortium for Systemic Lupus Erythematosus Genetics
Wake Forest University · USOklahoma Medical Research Foundation · USUniversity of Pittsburgh · USCooperative Research Centre for Tissue Growth and Repair · AUKing's College London · GBUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Michigan–Ann Arbor · USJohns Hopkins Medicine · USMedical University of South Carolina · USPediatric Nephrology of Alabama · USPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESSouthern California University for Professional Studies · USUniversity of California, Los Angeles · USUniversity of California, Riverside · USUniversity of Oklahoma Medical Center · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
University of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PENNATHUR, SUBRAMANIAM · 2008 to 2022
$12.9M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
The Interplay of Sociodemographic and Genetic Factors in SLE Health DisparitiesP60AR053308 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KATZ, PATRICIA P · 2006 to 2016
$11.8M
UAB Center for Clinical and Translational Science (CCTS) UL1UL1TR000165 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2012 to 2013
$9.6M
SequencingP01AI083194 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KIMBERLY, ROBERT P. · 2009 to 2013
$9.6M
Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
CHROMOSOME REGIONS LINKED TO SLE IN MULTIPLEX FAMILIESR01AR043814 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSAO, BETTY P · 1997 to 2012
$5.7M
Progression of Cardiovascular Disease in Lupus.R01AR046588 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MANZI, SUSAN · 2001 to 2010
$4.9M
Genetic Analysis of African American Hypertensive End-Stage Renal DiseaseR01DK070941 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FREEDMAN, BARRY IRA · 2006 to 2015
$4.7M
Arthritis Research UK 19289BLRD VA I01 BX001834NCATS NIH HHS KL2 TR000143NCATS NIH HHS KL2-TR000143NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1-TR000004NCATS NIH HHS UL1 TR000165NCATS NIH HHS UL1-TR000165NCRR NIH HHS UL1 RR025005NCRR NIH HHS UL1-RR025005NHLBI NIH HHS HL092397NHLBI NIH HHS R01 HL092397NHLBI NIH HHS R01-HL56266NIAID NIH HHS 3R37AI024717-23S1NIAID NIH HHS 5P01AI083194NIAID NIH HHS 5R37AI024717-25NIAID NIH HHS AI063274NIAID NIH HHS P01 AI083194NIAID NIH HHS R01 AI063274NIAID NIH HHS R37 AI024717NIAID NIH HHS R56 AI063274NIAMS NIH HHS 5P01AR049084NIAMS NIH HHS AR043247NIAMS NIH HHS AR052125NIAMS NIH HHS AR057028NIAMS NIH HHS AR43727NIAMS NIH HHS F32 AR050927NIAMS NIH HHS K23 AR063126NIAMS NIH HHS K24 AR002175NIAMS NIH HHS K24 AR002213NIAMS NIH HHS K24-AR002213NIAMS NIH HHS K24-AR02175NIAMS NIH HHS N01 AR062277NIAMS NIH HHS N01-AR062277NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P60 AR053308NIAMS NIH HHS P60-AR053308NIAMS NIH HHS R01 AR033062NIAMS NIH HHS R01-AR033062NIAMS NIH HHS R01 AR043727NIAMS NIH HHS R01 AR043814NIAMS NIH HHS R01-AR043814NIAMS NIH HHS R01 AR046588NIAMS NIH HHS R01-AR046588NIAMS NIH HHS R01 AR052125NIAMS NIH HHS R01 AR052300NIAMS NIH HHS R01-AR052300NIAMS NIH HHS R01 AR057028NIAMS NIH HHS R01 AR057172NIAMS NIH HHS R01-AR057172NIAMS NIH HHS RC2 AR058951NIAMS NIH HHS RC2-AR058951NIDDK NIH HHS P30 DK081943NIDDK NIH HHS P30-DK081943NIDDK NIH HHS R01 DK070941NIDDK NIH HHS R01-DK070941NIDDK NIH HHS R01 DK079912NIDDK NIH HHS R01-DK079912OCPHP CDC HHS PR094002Versus Arthritis 19289
6 · The paper itself

Abstract

Lupus nephritis is a manifestation of SLE resulting from glomerular immune complex deposition and inflammation. Lupus nephritis demonstrates familial aggregation and accounts for significant morbidity and mortality. We completed a meta-analysis of three genome-wide association studies of SLE to identify lupus nephritis-predisposing loci. Through genotyping and imputation, >1.6 million markers were assessed in 2000 unrelated women of European descent with SLE (588 patients with lupus nephritis and 1412 patients with lupus without nephritis). Tests of association were computed using logistic regression adjusting for population substructure. The strongest evidence for association was observed outside the MHC and included markers localized to 4q11-q13 (PDGFRA, GSX2; P=4.5×10(-7)), 16p12 (SLC5A11; P=5.1×10(-7)), 6p22 (ID4; P=7.4×10(-7)), and 8q24.12 (HAS2, SNTB1; P=1.1×10(-6)). Both HLA-DR2 and HLA-DR3, two well established lupus susceptibility loci, showed evidence of association with lupus nephritis (P=0.06 and P=3.7×10(-5), respectively). Within the class I region, rs9263871 (C6orf15-HCG22) had the strongest evidence of association with lupus nephritis independent of HLA-DR2 and HLA-DR3 (P=8.5×10(-6)). Consistent with a functional role in lupus nephritis, intra-renal mRNA levels of PDGFRA and associated pathway members showed significant enrichment in patients with lupus nephritis (n=32) compared with controls (n=15). Results from this large-scale genome-wide investigation of lupus nephritis provide evidence of multiple biologically relevant lupus nephritis susceptibility loci.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultAgedChildFemaleGenome-Wide Association StudyGenotypeHLA-DR2 AntigenHLA-DR3 AntigenHumansLupus Erythematosus, SystemicLupus NephritisMiddle AgedPhenotypePolymorphism, Single NucleotideHLA-DR2 AntigenHLA-DR3 AntigenRNA, Messengerepidemiologygenetic renal diseaselupus nephritisoutcomesSLE

Identifiers

PMID24925725
PMCPMC4243339
OpenAlexW2108049638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.